Xeris Biopharma Holdings, Inc. · NASDAQ:XERS
Xeris Biopharma — Technical Presentation (October 2022)
11 slides from Xeris Biopharma's technical presentation, Oct 20, 2022
Slide 1: Xeris Biopharma
Copyright ©2017-2022 Xeris Biopharma Holdings. All rights reserved. Xeris Biopharma (Nasdaq: XERS) A growth-oriented biopharmaceutical company committed to improving patient lives by developing and commercializing innovative products across a range of therapies Exhibit 99.2
Slide 2: Topline Results of Phase 1 Study of Levothyroxine: PO vs SC
Copyright ©2017-2022 Xeris Pharmaceuticals, Inc. All rights reserved. Topline Results of Phase 1 Study of Levothyroxine: PO vs SC (XP-8121-108) Agenda Opening Remarks: Paul Edick, Chairman and CEO Study Results: Ken Johnson, PharmD SVP, Global Development and Medical Affairs Q&A
Slide 3: Forward-looking statements
Copyright ©2017-2021 Xeris Pharmaceuticals, Inc. All rights reserved. Forward-looking statements 3 Any statements in this presentation about future expectations, plans and prospects for Xeris Biopharma Holdings, Inc., including the development of a sub- cutaneous formulation of levothyroxine, the ma
Slide 4: XeriSol Levothyroxine may enable 1x/weekly subcutaneous therapy
Copyright ©2017-2022 Xeris Pharmaceuticals, Inc. All rights reserved. XeriSol™ Levothyroxine may enable 1x/weekly subcutaneous (SC) therapy 4 With over 100M Rx/yr, oral levothyroxine is one of the most prescribed therapies in US XP-8121 — Levothyroxine For maintenance therapy in patients with congen
Slide 5: XP-8121-108: Study Overview
Copyright ©2017-2021 Xeris Pharmaceuticals, Inc. All rights reserved. XP-8121-108: Study Overview 5 • Background − Reliance on the FDA’s previous findings of safety and effectiveness for the listed drug, Synthroid® (Levothyroxine sodium tablets; NDA 21402 [Abbvie]); selected as reference standard fo
Slide 6: Phase 1 Pharmacokinetic Study Design (XP-8121-108)
Copyright ©2017-2021 Xeris Pharmaceuticals, Inc. All rights reserved. Phase 1 Pharmacokinetic Study Design (XP-8121-108) 6 PK results based on Baseline-Adjusted T4 Concentrations to determine: − Mean Concentration Profile Over Time − Key PK Parameters - Cmax, Tmax, AUCs
Slide 7: Baseline Adjusted T4 Concentration by Time Profile Day 1 to Day 28
Copyright ©2017-2022 Xeris Pharmaceuticals, Inc. All rights reserved. 0 2 4 6 8 10 12 14 16 18 20 22 24 26 28 0 10 20 30 40 50 60 Days From Dosing B as el in e- A dj us te d Pl as m a L ev ot hy ro xi ne C on ce nt ra tio n (n g/ m L ) XP-8121 600 μg SC Synthroid 600 μg PO Baseline Adjusted T4 Conce
Slide 8: Baseline Adjusted T4 Concentration by Time Profile Day 1 to Day 28
Copyright ©2017-2022 Xeris Pharmaceuticals, Inc. All rights reserved. Baseline Adjusted T4 Concentration by Time Profile Day 1 to Day 28 Following Single Dose Administration (XP-8121-108) 8 0 2 4 6 8 10 12 14 16 18 20 22 24 26 28 0 10 20 30 40 50 60 Days From Dosing B as el in e- A dj us te d Pl as
Slide 9: PopPK Model: Simulation of Chronic Dosing
Copyright ©2017-2022 Xeris Pharmaceuticals, Inc. All rights reserved. PopPK Model: Simulation of Chronic Dosing 9 XP-8121 SC 1200 µg/week has similar exposure to Synthroid PO 300 µg/day at steady state 0 1 2 3 4 5 6 7 0 20 40 60 80 100 120 y y Days Th yr ox in e (n g/ m L) - Si m ul at ed • All data
Slide 10: XP-8121 Highlights and Next Steps
Copyright ©2017-2022 Xeris Pharmaceuticals, Inc. All rights reserved. XP-8121 Highlights and Next Steps 10 • Large market opportunity: Oral levothyroxine is one of the most prescribed therapies in US with over 100 million prescriptions annually • Demonstrated proof-of-concept: A once weekly subcutan
Slide 11: Q&A
Copyright ©2017-2022 Xeris Biopharma Holdings. All rights reserved. Q&A
Xeris Biopharma Holdings — Technical Presentation (October 2022) on 6ix